ArticleAnesthesia and analgesia2026
Pharmacologic Reversal of Xylazine-Induced Unconsciousness in Rats.
Article in Anesthesia and analgesia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundXylazine is an alpha-2 adrenergic agonist approved for veterinary use as a sedative and analgesic for animals. Unfortunately, xylazine has recently become a common adulterant of street drugs in the United States with xylazine-related overdoses and deaths increasing each year. Although the alpha-2 adrenergic antagonist, atipamezole, is an efficacious reversal agent for xylazine that is approved for use in animals, it is not approved for humans. In this study, we aimed to test alternative reversal agents for xylazine, and compare them with atipamezole in a rat model of xylazine-induced unconsciousness.
methodsIn adult Sprague-Dawley rats, we induced loss of righting reflex (LORR, a surrogate end point for loss of consciousness) with xylazine (5 mg/kg, intravenous [IV]) and attempted to restore consciousness by administering agents with distinct molecular mechanisms of action: atipamezole (alpha-2 adrenergic antagonist, 200 µg/kg IV); d-amphetamine (norepinephrine and dopamine reuptake inhibitor and releasing agent, 1 mg/kg); chloro-APB (dopamine D1 receptor agonist, 3 mg/kg IV); and atomoxetine (norepinephrine reuptake inhibitor, 3 mg/kg IV). Pulse oximetry and heart rate were monitored continuously. After administration of the reversal agents, time to return of righting reflex (RORR) was recorded (n = 12) and animals were assessed with a novel object recognition test (n = 17). One subset of animals underwent surgery to have electroencephalogram (EEG) leads implanted (n = 4). EEG data were recorded after xylazine injection and ensuing administration of a reversal agent and spectral analysis was performed.
resultsAfter xylazine-induced unconsciousness, the median time to RORR in atipamezole-, d-amphetamine-, and chloro-APB-treated rats was 1.5 minutes (Interquartile Range [1.0-2.0]), 2 minutes (interquartile range [IQR] [1.0-3.0]), and 2 minutes (IQR [1.0-2.0]) post drug injection, respectively, compared to 56 minutes (IQR [39.5-70.5]) after saline control ( F [4,40] = 41.62, P < .0001). Atomoxetine did not significantly accelerate time to RORR. During the novel object recognition test, all animals spent the same amount of time with the familiar and novel object (range 0-143.5 sec), indicating that no reversal agents restored recognition memory. Xylazine induced an EEG pattern dominated by slow-delta oscillations. Atipamezole, d-amphetamine, and chloro-APB restored EEG oscillations similar to the awake state.
conclusionsAtipamezole, d-amphetamine, and chloro-APB accelerate emergence from xylazine-induced unconsciousness and restore EEG oscillation patterns consistent with wakefulness. However, none of these reversal agents restore recognition memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.